ARULATAN

This brand name is authorized in Brazil, Estonia, Germany, Romania, Spain, Turkey.

Active ingredients

The drug ARULATAN contains one active pharmaceutical ingredient (API):

1	Latanoprost UNII 6Z5B6HVF6O - LATANOPROST
	The active substance latanoprost, a prostaglandin F2α analogue, is a selective prostanoid FP receptor agonist which reduces the intraocular pressure (IOP) by increasing the outflow of aqueous humour. Reduction of the IOP in man starts about three to four hours after administration and maximum effect is reached after eight to twelve hours.
	Read more about Latanoprost

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
S01EE01	Latanoprost	S Sensory organs → S01 Ophthalmologicals → S01E Antiglaucoma preparations and miotics → S01EE Prostaglandin analogues
Discover more medicines within S01EE01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
BR	Câmara de Regulação do Mercado de Medicamentos	503115110001304
DE	Bundesinstitut für Arzneimittel und Medizinprodukte	09241142, 09241159, 10354762
EE	Ravimiamet	1370573, 1370584, 1370595
ES	Centro de información online de medicamentos de la AEMPS	72964
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W56354001, W56354002, W56354003
TR	İlaç ve Tıbbi Cihaz Kurumu	8699293615903